In this episode of the Spotlight Media Podcast, Dennis Walker speaks with Edward Crowe – music industry executive, photographer, and psychonaut – about how his relationship with psilocybin mushrooms helps him navigate his personal and professional life.
Numinus Acquiring Novamind in First Major Psychedelics Merger
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd: www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Not only will this be your chance to meet me, but also the legendary Paul Stamets!
Join our Newsletter (scroll to the bottom of the page and sign up): https://psychedelicspotlight.com/psyc…
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PsycInvestor
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@thepsychedelicinvestor
@psycspotlight
To learn more about the emerging psychedelic industry, visit:
https://psychedelicspotlight.com/
Back to Numinus
This acquisition will make Numinus the psychedelic medicines company with the highest revenue, though of course there is still a long road to profitability.
Psychedelic stock investors woke up to some major news today: Numinus Wellness (TSX: NUMI) (OTCQX: NUMIF) announced that they are acquiring Novamind Inc. (CSE: NM) (OTCQB: NVMDF).
The acquisition will be done in stock, and shareholders of Novamind will receive 0.84 of a common share of Numinus per Novamind share held, implying an offer price of $0.44 per Novamind share. This means Numinus is offering a premium of 51% to Novamind shareholders, based on the 20-day volume-weighted average price of their stock. When the transaction is completed, Novamind shareholders will own around 18% of Numinus.
If you currently hold Novamind stock, you do not need to do anything. When the transaction is finalized, each Novamind share you own will automatically be transformed into 0.84 of a Numinus share.
#Numinus #NovaMind #psychedelicStocks
In this episode of the Psychedelic Spotlight podcast, we spend some time with Tesla La Touche who is the Founder and CEO of Aphrodite Health, the first ever female-founded biotech company within the medicinal psychedelic industry.
What exactly are psilocybin mushroom spores? Are they legal? Here’s everything you need to know and how to grow your own.
The momentum is snowballing, and 2021 will be even bigger and better for psychedelics. After a year like 2020, it’s hard to know what the next year will bring. But we’ve got a feeling it’s going to be quite the ride for psychedelics.
Chief Medical Officer Dr. Guy Goodwin clarifies “COMP360 psilocybin therapy was generally well-tolerated” by patients with treatment-resistant depression, despite some adverse reactions from subjects in the study.
We dive into the world of the infamous Amanita Muscaria mushroom and learn about the wild desert apothecary of fungi and herbs.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
